BioWorld MedTech

July 14, 2016

Feds request additional information about Abbott's $25 billion merger with St. Jude, putting possible divestments in the cards

The U.S. Federal Trade Commission requested more information about the impending $25 billion merger of St. Jude Medical Inc. and Abbott Laboratories, meaning the earliest date at which the deal can close has been extended by 30 days. Read More

China's PMI moving forward; NHFPC names 61 projects for funding

Resilia to team up with South African distributor to market Uresta device

Clearbridge, Cambridge partner to birth, nurture Asian startup companies

Patients deserve a stronger voice in clinical trial design

Other news to note

Financings

Daily M&A

Product briefs

MDD's Orthopedics

Today's news in brief

BioWorld

BioWorld briefs for May 21, 2026.

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

News in brief

BioWorld Asia

BioWorld Asia briefs for May 19, 2026

WHO declares Ebola outbreak a public health emergency of international concern

BioWorld

The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...

Nxera Pharma prepares and tests new GPR17 antagonists

BioWorld Science

Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...